Maxcyte, INC Schedule 13G passive stakes

Mirabella Financial Services LLP has filed a Schedule 13G, reporting zero shares beneficially owned in Maxcyte, Inc. as of March 31, 2026, due to no longer acting as Investment Manager for Blue Riband Fund LP.

The Vanguard Group filed an amended Schedule 13G, reporting 0% beneficial ownership in MaxCyte Inc. following an internal corporate realignment.

Cadian Capital Management and its affiliates reported a 3.5% beneficial ownership stake in MaxCyte, Inc. as of December 31, 2025.

Capricorn Fund Managers Ltd has reported a 7.7% beneficial ownership stake in MAXCYTE, INC. common stock.

BlackRock, Inc. has disclosed an increased beneficial ownership of 6.6% in MAXCYTE, INC.'s common stock, totaling 6,997,197 shares.

Cadian Capital Management and affiliates report a 7.7% beneficial ownership stake in MaxCyte, Inc., holding over 8.2 million shares.

Mirabella Financial Services LLP has reported a 7.69% beneficial ownership stake in MAXCYTE, INC. common stock as of September 30, 2025.

Mirabella Financial Services LLP has reported a 6.2% beneficial ownership stake in MAXCYTE, INC., holding 6.6 million shares.

Cadian Capital Management, LP, along with its general partner and Eric Bannasch, has disclosed a beneficial ownership of 8.9% in MaxCyte, Inc., holding 9,344,424 shares as of December 31, 2024.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 7.8% of MaxCyte, Inc.'s common stock as of December 31, 2024.